Anti-EGFR Antibody Reduces Lung Nodules by Inhibition of EGFR-Pathway in a Model of Lymphangioleiomyomatosis

Figure 5

30 weeks after administration LAM/TSC cells cause an increase of blood and lymphatic vessels which is counteracted by anti-EGFR Ab. (a) Representative images of lungs stained with hematoxylin and eosin are shown. Scale bars: 200 μm. (b) Quantification of blood vessels is done by counting the number of vessels in a field (6 fields for 8 mice for each group). Data are expressed as mean ± SEM. versus control mice. ^## versus LAM/TSC-administered mice. (c) Lymphatic capillary marker LYVE-1 (green labelling) is expressed in lung nodules and is inhibited by anti-EGFR Ab and rapamycin. Sections are stained with DAPI to show nuclei (blue). Representative images are shown. Scale bars: 75 μm. (d) LVD is calculated in five fields of lung parenchyma for each mouse. Data are expressed as mean ± SEM. versus LVD of control mice. ^## versus LVD of LAM/TSC-administered mice.

(a)

(b)

(c)

(d)